Sanofi gets binding bids for consumer unit
Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports
Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, from private equity firms Clayton Dubilier & Rice and PAI Partners,
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.
Clayton Dubilier & Rice made it a condition for banks to commit more than €1 billion ($1.1 billion) of debt to fund a part of ...
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms ...
Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...
French drugmaker Sanofi has confirmed its plan to spend €1.3bn on an insulin factory at its site near Frankfurt, website ...
AbbVie's (NYSE:ABBV) autoimmune disease biologic Humira (adalimumab) and Pfizer (NYSE:PFE)/BioNTech's (BNTX) COVID-19 shot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback